[{"address1": "25 North 38th Street", "address2": "11th Floor", "city": "Philadelphia", "state": "PA", "zip": "19104", "country": "United States", "phone": "267 817 5790", "website": "https://www.centurytx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.", "fullTimeEmployees": 152, "companyOfficers": [{"maxAge": 1, "name": "Mr. Brent  Pfeiffenberger M.B.A., Pharm.D.", "title": "CEO & Director", "fiscalYear": 2023, "totalPay": 274065, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Adrienne  Farid Ph.D.", "age": 61, "title": "COO & Head of Early Development", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 670289, "exercisedValue": 0, "unexercisedValue": 509880}, {"maxAge": 1, "name": "Dr. Gregory  Russotti Ph.D.", "age": 56, "title": "Chief Technology & Manufacturing Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 852564, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas  Carr CPA", "title": "Interim Principal Financial Officer, Senior VP of Finance & Operations and Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kenneth J. Dow J.D.", "title": "Senior VP of General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shane  Williams Ph.D.", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hyam I. Levitsky M.D.", "age": 65, "title": "President of Research & Development", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 502125, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Michael  Naso Ph.D.", "title": "Senior VP of Cell Engineering", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nick  Trede M.D., Ph.D.", "title": "Senior VP & Head of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.59, "open": 1.61, "dayLow": 1.4301, "dayHigh": 1.8, "regularMarketPreviousClose": 1.59, "regularMarketOpen": 1.61, "regularMarketDayLow": 1.4301, "regularMarketDayHigh": 1.8, "beta": 1.37, "forwardPE": -0.7783784, "volume": 659432, "regularMarketVolume": 659432, "averageVolume": 330458, "averageVolume10days": 401820, "averageDailyVolume10Day": 401820, "bid": 1.43, "ask": 1.46, "bidSize": 400, "askSize": 600, "marketCap": 125059976, "fiftyTwoWeekLow": 1.28, "fiftyTwoWeekHigh": 5.51, "priceToSalesTrailing12Months": 61.273872, "fiftyDayAverage": 2.1407, "twoHundredDayAverage": 3.08795, "currency": "USD", "enterpriseValue": -5327622, "floatShares": 33528036, "sharesOutstanding": 84716000, "sharesShort": 2234707, "sharesShortPriorMonth": 2867153, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.026400002, "heldPercentInsiders": 0.28213, "heldPercentInstitutions": 0.58929, "shortRatio": 8.69, "shortPercentOfFloat": 0.0323, "bookValue": 2.627, "priceToBook": 0.5481538, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -131387000, "trailingEps": -2.02, "forwardEps": -1.85, "pegRatio": 0.06, "enterpriseToRevenue": -2.61, "enterpriseToEbitda": 0.046, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "IPSC", "underlyingSymbol": "IPSC", "shortName": "Century Therapeutics, Inc.", "longName": "Century Therapeutics, Inc.", "firstTradeDateEpochUtc": 1624023000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f95000f0-82eb-31c4-9606-6aa49d9bac06", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.44, "targetHighPrice": 12.0, "targetLowPrice": 6.0, "targetMeanPrice": 10.2, "targetMedianPrice": 12.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 196402000, "totalCashPerShare": 2.318, "ebitda": -114721000, "totalDebt": 56376000, "quickRatio": 10.341, "currentRatio": 10.618, "totalRevenue": 2041000, "debtToEquity": 25.383, "revenuePerShare": 0.031, "returnOnAssets": -0.1924, "returnOnEquity": -0.55948, "freeCashflow": -62074376, "operatingCashflow": -97459000, "revenueGrowth": 6.788, "operatingMargins": -45.077824, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]